Welcome to our dedicated page for KAZIA THERAPEUTICS SEC filings (Ticker: KZIA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on KAZIA THERAPEUTICS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into KAZIA THERAPEUTICS's regulatory disclosures and financial reporting.
KAZIA THERAPEUTICS LTD (KZIA) filed a prospectus supplement registering 10,700,211 American Depositary Shares (ADSs) representing 5,350,105,500 ordinary shares, and updates its Form F-1 prospectus by incorporating a new Form 6-K. The ADSs trade on Nasdaq under KZIA, last at $13.77 per ADS on August 31, 2026.
The attached Form 6-K adds two press releases on lead asset paxalisib. In microsatellite stable / proficient mismatch repair colorectal cancer, paxalisib monotherapy reduced tumor burden by 52%, and adding pembrolizumab cut tumor volume by a further 50% versus immunotherapy alone, with treatment reported as well tolerated in preclinical models. Kazia plans a five-arm Phase 2 trial in pre-treated MSS/pMMR metastatic colorectal cancer, with enrollment expected to begin in the first quarter of 2027 and complete by year-end 2027.
A second release reports preclinical data in HR+/HER2- breast cancer, including activity in CDK4/6 inhibitor–resistant tumors, and protocol expansion of an ongoing TNBC trial to three arms testing paxalisib plus fulvestrant, with palbociclib, versus standard-of-care fulvestrant. The company targets first patient before year-end 2026, full enrollment by the end of 2027, and a full readout in 2028. Kazia highlights biomarker and patent work to support biomarker-driven development and intellectual property around paxalisib’s use in these indications.
Kazia Therapeutics Limited (KZIA) filed a prospectus supplement covering 232,956 American Depositary Shares (ADSs), representing 116,478,000 ordinary shares, and updating its F-1 prospectus with new clinical and preclinical information. The ADSs trade on Nasdaq under the symbol KZIA, with a last reported price of $13.77 per ADS on August 31, 2026.
Kazia reports preclinical data showing its lead asset paxalisib reduced tumor burden by 52% in microsatellite stable/proficient mismatch repair colorectal cancer, and in combination with pembrolizumab achieved a further 50% tumor volume reduction versus immunotherapy alone, with good tolerability. The company plans a five-arm Phase 2 trial in pre-treated MSS/pMMR metastatic colorectal cancer and expects enrollment to run through 2027. Separately, new preclinical data in HR+/HER2- breast cancer support expanding an ongoing TNBC trial into a three-arm study testing paxalisib plus fulvestrant, with or without palbociclib, versus standard of care, with first patient targeted by year-end 2026 and full enrollment by the end of 2027.
Kazia Therapeutics Limited (KZIA) filed a prospectus supplement for an existing Form F-1 registration covering 266,666 American Depositary Shares, each ADS representing in total 133,333,000 ordinary shares, and updated the document by attaching a new Form 6-K. The ADSs trade on Nasdaq under symbol KZIA, with a last reported price of $13.77 per ADS on August 31, 2026.
The attached Form 6-K includes two press releases on preclinical data for KZIA’s lead asset, paxalisib. In microsatellite stable / proficient mismatch repair colorectal cancer, paxalisib reduced tumor burden by 52%, and adding paxalisib to an immunotherapy reduced tumor volume by a further 50%, with treatment well tolerated; Kazia plans a five-arm Phase 2 trial in this setting with enrollment targeted for 2027. A second release reports preclinical data in HR+/HER2- breast cancer showing statistically significant antitumor activity and resensitization of CDK4/6 inhibitor-resistant tumors, supporting a three-arm expansion of an ongoing TNBC trial, with first patient expected by year-end 2026 and full enrollment by end of 2027. The company is also advancing biomarker programs and patent filings related to paxalisib and incorporates these disclosures by reference into multiple Form F-3 registration statements.
Kazia Therapeutics Limited (KZIA) filed a prospectus supplement to its Form F-1, referencing an offering of 95,110 American Depositary Shares (ADSs) representing 47,555,000 ordinary shares, and incorporating a new Form 6-K. The ADSs trade on Nasdaq under KZIA, with a last reported price of $13.77 per ADS on August 31, 2026.
The attached Form 6-K highlights preclinical data for lead asset paxalisib in difficult-to-treat cancers. In microsatellite stable / proficient mismatch repair colorectal cancer, paxalisib monotherapy reduced tumor burden by 52%, and adding paxalisib to an immunotherapy reduced tumor volume by a further 50%, with treatment described as well tolerated. Kazia plans a five-arm Phase 2 trial in this setting, targeting first patient enrollment in the first quarter of 2027 and full enrollment by year-end 2027.
Additional preclinical data in HR+/HER2- breast cancer showed statistically significant antitumor activity and resensitization of CDK4/6 inhibitor–resistant tumors to standard therapy. Kazia will expand an ongoing TNBC trial with a three-arm HR+/HER2- cohort, aiming for first patient by year-end 2026, full enrollment by end-2027, and a full data readout in 2028.
Kazia Therapeutics Limited (KZIA) reported new preclinical and translational data for its lead PI3K/Akt/mTOR inhibitor, paxalisib, and outlined plans for multiple Phase 2 trials in colorectal and breast cancer. In microsatellite stable / proficient mismatch repair (MSS/pMMR) colorectal cancer, paxalisib monotherapy reduced tumor burden by 52% (p=0.035) in a preclinical model, and adding paxalisib to an existing immunotherapy reduced tumor volume by an additional 50% versus immunotherapy alone (p=0.022), with no treatment-related toxicity observed across studies.
For MSS/pMMR metastatic colorectal cancer, which accounts for approximately 85–90% of metastatic cases, Kazia plans a five‑arm Phase 2 trial comparing different paxalisib doses (15 mg and 30 mg), alone and with pembrolizumab, against a standard‑of‑care arm. The primary endpoint is safety and tolerability, with progression‑free survival, overall response rate and overall survival as secondary endpoints. Enrollment is expected to begin in the first quarter of 2027, with full enrollment of all five arms targeted by the end of 2027.
Kazia also reported preclinical data in HR+/HER2‑ breast cancer showing that paxalisib, combined with standard‑of‑care therapies such as fulvestrant and palbociclib, produced statistically significant antitumor activity and consistent safety, including resensitization of CDK4/6 inhibitor‑resistant tumors. HR+/HER2‑ disease represents approximately 60–70% of all breast cancer diagnoses, with an estimated 322,000 new U.S. cases this year. The company is adding a three‑arm expansion to its ongoing TNBC trial in pre‑treated HR+/HER2‑ metastatic breast cancer, with two paxalisib plus fulvestrant plus palbociclib arms (15 mg and 30 mg) versus a fulvestrant standard‑of‑care arm. First patient enrollment is expected before the end of 2026, full enrollment by the end of 2027, and a full data readout anticipated in 2028. Kazia has also filed related patent applications and is advancing biomarker programs to enable biomarker‑driven development of paxalisib.
Kazia Therapeutics Limited (KZIA) filed a prospectus supplement to its Form F-1 prospectus covering 10,700,211 American Depositary Shares (ADSs), which represent 5,350,105,500 ordinary shares. The supplement incorporates a Form 6-K describing the launch of a new corporate website.
The company has changed its primary website to www.kaziatx.com, and prior references to www.kaziatherapeutics.com in its SEC filings should now be read as referring to the new URL. The ADSs trade on the Nasdaq Capital Market under the symbol KZIA, with a last reported sale price of $13.58 per ADS on August 28, 2026. The Form 6-K is also incorporated by reference into Kazia’s effective Form F-3 registration statements.
KAZIA THERAPEUTICS LTD (KZIA) filed a prospectus supplement to its Form F-1 registration statement describing an offering of 232,956 American Depositary Shares (ADSs), representing 116,478,000 ordinary shares
The attached Form 6-K reports that on August 28, 2026, Kazia launched a new corporate website at www.kaziatx.com, replacing prior references to www.kaziatherapeutics.com. The company states the site is intended to improve access to information on its business, products, services, clinical trials, and corporate developments. The Form 6-K is also incorporated by reference into three existing Form F-3 registration statements.
Kazia Therapeutics Limited (KZIA) has filed a prospectus supplement to its Form F-1 registration statement covering 266,666 American Depositary Shares (ADSs), each ADS representing 500 ordinary shares for a total of 133,333,000 ordinary shares. The supplement updates the existing prospectus by incorporating a Form 6-K dated August 31, 2026, which reports that on August 28, 2026 the company launched a new website at www.kaziatx.com, replacing prior references to www.kaziatherapeutics.com. The ADSs trade on the Nasdaq Capital Market under the symbol KZIA, and the last reported sale price on August 28, 2026 was $13.58 per ADS. The information in this Form 6-K is also incorporated by reference into Kazia’s registration statements on Form F-3 (File Nos. 333-276091, 333-281937 and 333-294392).
Kazia Therapeutics Limited (KZIA) filed a prospectus supplement under its Form F-1 registration statement to update the prospectus for an offering of 95,110 American Depositary Shares (ADSs), representing 47,555,000 ordinary shares. The supplement incorporates information from a Form 6-K dated August 31, 2026.
Kazia reports that on August 28, 2026 it launched a new website at www.kaziatx.com, and prior references to www.kaziatherapeutics.com in its SEC materials should be read to refer to the new URL. The ADSs trade on the Nasdaq Capital Market under the symbol KZIA, with a last reported sale price of $13.58 per ADS on August 28, 2026. The Form 6-K content is also incorporated by reference into Kazia’s Form F-3 registration statements (File Nos. 333-276091, 333-281937 and 333-294392).
Kazia Therapeutics Limited (KZIA) reports that on August 28, 2026 it launched a new corporate website at www.kaziatx.com. Any prior references to its former website, including www.kaziatherapeutics.com, are now intended to refer to the new URL where applicable.
The site is described as providing enhanced access to information about Kazia’s business, products, services, clinical trials, and corporate developments, and stakeholders are encouraged to review information posted there alongside press releases and SEC disclosures. The information in this report is incorporated by reference into Kazia’s existing Form F-3 registration statements.